Infusion reactions that can sometimes be severe or life-threatening. Signs and symptoms of infusion reactions may include: ...

Sanofi's rash of dealmaking has continued with a $ ... by its Regeneron-partnered PD-1 checkpoint inhibitor Libtayo (cemiplimab), which still has modest sales, and the drugmaker has been keen ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN FRANCISCO -- A combination of cemiplimab (Libtayo) and standard-of-care chemotherapy appeared to be effective in ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results demonstrat ...

At 12 weeks, the clinical benefit rate was 62.1%, and the objective response rate was 51.7%. First-line cemiplimab and platinum-based chemotherapy appears to be safe and effective for patients ...

Contact dermatitis is a common cause of a rash in one area. This is especially true of a small rash that will not go away. Contact dermatitis usually starts as raised red spots. It can change to ...

Dr. Amarnath Challapalli presented the Abstract 9: EPIC-B: Phase II trial of cemiplimab as first-line treatment in advanced penile carcinoma. Patients with locally advanced or metastatic penile ...

Symptoms can include itching, dryness, bumps, rash, blisters, or swelling. Contact dermatitis can occur on any part of the body, including the elbows. There are two broad categories of contact ...